Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 878.1% in July

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 433,300 shares, anincreaseof878.1% from the July 15th total of 44,300 shares. Based on an average trading volume of 370,900 shares, the short-interest ratio is presently 1.2 days. Approximately1.8% of the shares of the company are short sold. Approximately1.8% of the shares of the company are short sold. Based on an average trading volume of 370,900 shares, the short-interest ratio is presently 1.2 days.

Anebulo Pharmaceuticals Trading Up 2.5%

NASDAQ:ANEB opened at $2.50 on Friday. Anebulo Pharmaceuticals has a twelve month low of $0.80 and a twelve month high of $3.42. The company has a 50-day moving average of $1.98 and a 200-day moving average of $1.48. The firm has a market cap of $102.70 million, a price-to-earnings ratio of -9.62 and a beta of -0.88.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. On average, research analysts forecast that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Maxim Group lowered shares of Anebulo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 23rd.

Institutional Trading of Anebulo Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ANEB. 22NW LP grew its holdings in shares of Anebulo Pharmaceuticals by 188.2% during the fourth quarter. 22NW LP now owns 15,467,300 shares of the company’s stock valued at $25,985,000 after buying an additional 10,101,010 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Anebulo Pharmaceuticals by 494.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,036,325 shares of the company’s stock worth $5,101,000 after acquiring an additional 2,525,252 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new position in Anebulo Pharmaceuticals during the 1st quarter valued at about $62,000. 28.40% of the stock is owned by institutional investors and hedge funds.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.